28 Mar Gut and Pancreatic Microbiome Drive Pancreatic Cancer

MedicalResearch.com Interview with:

Dr. Hundeyin

Mautin Hundeyin MD
Post-doctoral Research Fellow

George Miller, MD is Principal Investigator and Director of the S. Arthur Localio Laboratory in the Department of Surgery at NYU School of Medicine

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Pancreatic ductal adenocarcinoma (PDA) is the devastating disease with grim prognosis. The microbiome has emerged as a contributor to oncogenesis in a number of intestinal tract malignancies. We found that PDA is associated with a distinct stage-specific gut and pancreatic microbiome that drives disease progression by inducing intra-tumoral immune suppression. Targeting the microbiome protects against oncogenesis, reverses intra-tumoral immune-tolerance, and enables efficacy for check-point based immunotherapy. These data have implications for understanding immune-suppression in pancreatic cancer and its reversal in the clinic. 

MedicalResearch.com: What should readers take away from your report?

Response: Our data suggests that elements of the microbiome may be useful in early diagnosis and risk stratification. Further, microbial-targeted therapies may reduce risk in pre-invasive disease and may be used as an adjuvant to standard therapies or in synergy with checkpoint-directed immunotherapy in invasive disease.

MedicalResearch.com: What recommendations do you have for future research as a result of this work? 

Response: Prospective studies are necessary for identification of microbial signatures with tumor specificity that may have potential for early diagnosis and risk stratification.

No disclosures 

Citations:

Smruti Pushalkar, Mautin Hundeyin, Donnele Daley, Constantinos P. Zambirinis, Emma Kurz, Ankita Mishra, Navyatha Mohan, Berk Aykut, Mykhaylo Usyk, Luisana E. Torres, Gregor Werba, Kevin Zhang, Yuqi Guo, Qianhao Li, Neha Akkad, Sarah Lall, Benjamin Wadowski, Johana Gutierrez, Juan Andres Kochen Rossi, Jeremy W. Herzog, Brian Diskin, Alejandro Torres-Hernandez, Josh Leinwand, Wei Wang, Pardeep S. Taunk, Shivraj Savadkar, Malvin Janal, Anjana Saxena, Xin Li, Deirdre Cohen, R. Balfour Sartor, Deepak Saxena, George Miller. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discovery, 2018; DOI: 10.1158/2159-8290.CD-17-1134

[wysija_form id=”3″] 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on March 28, 2018 by Marie Benz MD FAAD